This is repository of my old source code which isn't updated any more. Go to git.rot13.org for current projects!
ViewVC logotype

Contents of /news/49.html

Parent Directory Parent Directory | Revision Log Revision Log

Revision 1.2 - (show annotations)
Sat Mar 3 08:32:51 2001 UTC (19 years, 4 months ago) by dpavlin
Branch: MAIN
Changes since 1.1: +1 -1 lines
File MIME type: text/html
added missing mailto:

2 <p> PLIVA d.d. ("PLIVA") announced today that it has acquired Pharmascience UK
3 Limited, 100% owner of Dominion Pharma Limited ("Dominion"), for a total cash
4 consideration of GBP 3.4 million.</p>
5 <p> Dominion, who reported a turnover of GBP 4.3 million in 1999, markets a mix
6 of speciality branded products, together with a growing range of generics, for
7 both primary and secondary care. The speciality product range mainly comprises
8 products in the urological, ophthalmological and dermatological areas, and is
9 supported by a small hospital specialist sales team. The generic range is sold
10 directly to wholesalers and hospitals with some products being supplied to other
11 pharmaceutical companies for marketing under their own brand name. The company
12 seeks to grow through the development, licensing-in and acquisition of both
13 speciality and selected generic products. </p>
14 <p>The value of the company lies in its pipeline of new product agreements; the
15 ownership of certain licences through which it also carries out contract manufacturing
16 for third parties; the skilled management and staff with their knowledge and
17 expertise in both the UK and other Western European markets; as well as the
18 current range of branded niche products. The transaction will not, however,
19 involve the acquisition of any manufacturing assets. </p>
20 <p>Commenting on the acquisition, Zeljko Covic, President and Chief Executive
21 Officer of PLIVA, stated: "The acquisition of Dominion, which provides the benefits
22 of direct access to the important UK market as well as a team of experienced
23 staff, represents the first step in the implementation of PLIVA's strategy to
24 enter key identified markets in the West. We expect growth on UK market from
25 both Dominion products and PLIVA's generics in development. Currently, PLIVA
26 is considering further acquisitions and start-up operations both in the UK and
27 other Western markets. This transaction highlights our commitment to internationalising
28 our business and securing a firm financial and operational basis for PLIVA's
29 future, enabling PLIVA to continue to create and deliver additional shareholder
30 value.&quot;</p>
31 <p> For additional information please contact: </p>
32 <p>Erika Kaspar<br>
33 Investor Relations, Director<br>
34 Tel: 385 1 6120 755<br>
35 Fax: 385 1 6114 413<br>
36 E-mail: <a href="mailto:erika.kaspar@pliva.hr">Erika.Kaspar@pliva.hr</a></p>
37 <p> Marija Mandic<br>
38 Finance, Financial Analyst<br>
39 Tel: 385 1 6160 355<br>
40 Fax: 385 1 6120 634<br>
41 E-mail: <a href="mailto:marija.mandic@pliva.hr">Marija.Mandic@pliva.hr</a></p>

  ViewVC Help
Powered by ViewVC 1.1.26